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Abstract
Background: Provision of evidence on costs alongside evidence on the effects of interventions can enhance the
relevance of systematic reviews to decision-making. However, patterns of use of economics methods alongside
systematic review remain unclear. Reviews of evidence on the effects of interventions are published by both the
Cochrane and Campbell Collaborations. Although it is not a requirement that Cochrane or Campbell Reviews should
consider economic aspects of interventions, many do. This study aims to explore and describe approaches to
incorporating economics methods in a selection of Cochrane systematic reviews in the area of health promotion and
public health, to help inform development of methodological guidance on economics for reviewers.
Methods: The Cochrane Database of Systematic Reviews was searched using a search strategy for potential economic
evaluation studies. We included current Cochrane reviews and review protocols retrieved using the search that are also
identified as relevant to health promotion or public health topics. A reviewer extracted data which describe the
economics components of included reviews. Extracted data were summarised in tables and analysed qualitatively.
Results: Twenty-one completed Cochrane reviews and seven review protocols met inclusion criteria. None
incorporate formal economic evaluation methods. Ten completed reviews explicitly aim to incorporate economics
studies and data. There is a lack of transparent reporting of methods underpinning the incorporation of economics
studies and data. Some reviews are likely to exclude useful economics studies and data due to a failure to incorporate
search strategies tailored to the retrieval of such data or use of key specialist databases, and application of inclusion
criteria designed for effectiveness studies.
Conclusion: There is a need for consistency and transparency in the reporting and conduct of the economics
components of Cochrane reviews, as well as regular dialogue between Cochrane reviewers and economists to develop
increased capacity for economic analyses alongside such reviews. Use of applicable economics methods in Cochrane
reviews can help provide the international context within which economics data can be interpreted and assessed as a
preliminary to full economic evaluation.
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Evidence on 'what works' is central to the formulation of
public sector policy and practice. High quality systematic
reviews can provide robust and comparatively inexpen-
sive evidence of what is known about intervention effec-
tiveness, which may often be more likely to convince
decision-makers than evidence from single studies [1,2].
The Cochrane Collaboration and Campbell Collabora-
tion are parallel international organisations committed to
summarising and providing access to evidence on the
effects and other aspects of interventions using systematic
review methods. This involves the systematic identifica-
tion, critical review and synthesis (typically using a meta-
analysis) of evidence on main clinical effectiveness (incor-
porating adverse events and complications) – evidence
primarily extracted from randomised controlled trials.
The aim is to maximise the precision of estimates of effec-
tiveness (or, alternatively, to minimise bias in such esti-
mates) by selecting studies based on predetermined
criteria, including study quality. Cochrane focuses on
health care interventions, whilst Campbell focuses on
education, criminal justice and social welfare interven-
tions. There is nevertheless some overlap in focus of inter-
est between the Collaborations where interventions,
client groups, important outcomes, or aspects of review
methodology cross these policy areas.
Cochrane and Campbell reviews are not currently
required to incorporate an economics component. How-
ever, it is increasingly accepted that provision of evidence
on intervention costs alongside evidence on effectiveness
can significantly enhance the relevance and usefulness of
Cochrane and other systematic reviews as a component of
the basis for decision-making by managers and policy
makers [3]. Evidence regarding the economics of interven-
tions is useful at various stages of knowledge about their
effectiveness. The relationship between expected changes
in effects and costs determines the type and degree of
added value from the intervention. Clearly if outcomes
are improved or not changed and costs are reduced, a
technology will be economically efficient. However,
where there is likely to be a high overall cost of improving
outcomes, decision makers will need to consider if this is
the best use of resources. Finally, where outcomes are
actually worse as a result of a form of care, the cost of
changing practice to avoid that form of care also needs to
be considered. Cochrane and Campbell reviewers increas-
ingly encounter economics studies conducted alongside
the randomised controlled trials and other studies
included in their reviews. These factors have led to
increased numbers of Cochrane reviews, and a small
number of Campbell Reviews, incorporating some eco-
nomics aspects.
Economic evaluation is the comparative analysis of alter-
native courses of action in terms of both their costs
(resource use) and consequences (effectiveness) [4]. We
use the term 'evidence-based economic evaluation' to dis-
tinguish forms of full economic evaluation based on sys-
tematic review and research synthesis methods from those
based on a single primary study, such as economic evalu-
ations conducted alongside randomised controlled trials.
Although the latter can clearly be of high research quality,
they may not include all available and relevant evidence
in their analyses for policy decisions. Evidence-based eco-
nomic evaluation is increasingly used to inform policy
decisions falling under the auspices of organisations with
national responsibilities for health technology assessment
and guidance on the prevention and treatment of ill
health (e.g. National Institute for Health and Clinical
Excellence (NICE); US Center for Disease Control and
Prevention (CDC); Canadian Agency for Drugs and Tech-
nology in Health (CADTH, formerly CCHOTA); Austral-
ian Pharmaceutical Benefits Advisory Committee
(PBAC)).
Whilst the details of methodological requirements for
such studies vary across these agencies [5], evidence-based
economic evaluation essentially sets out to estimate, or
model, the joint distribution of costs and effects resulting
from a health care intervention or programme, compared
to its alternatives, within a defined population, by system-
atically identifying and synthesising the best available
sources of data on five key parameters: main clinical effec-
tiveness, adverse events and complications; baseline clin-
ical events; resource use and unit costs; and utilities (or
other measures of preferences for health states) [6]. The
aim is to maximise the precision of estimates of these
parameters (or, alternatively, to minimise bias in their
estimation), so that residual uncertainty associated with
estimates of incremental cost-effectiveness (joint costs
and effects) is minimised. A useful decision-aid, in the
form of graphical presentation of costs and effectiveness
outcomes, is a 'cost-effectiveness plane' (or 'cost-effective-
ness matrix') [7].
A well-conducted meta-analysis of randomised controlled
trials, with direct comparison between alternative inter-
ventions, has been proposed as the least-biased source of
evidence to inform ranges of values for the main clinical
effectiveness parameter in an evidence-based economic
evaluation [6,8]. Indeed, for this reason, companion sys-
tematic reviews of effectiveness studies (or 'effectiveness
reviews') often provide a natural vehicle for evidence-
based economic evaluations, such as those undertaken for
NICE. Similarly, Cochrane (or Campbell) reviews incor-
porating a meta-analysis can provide an unbiased source
for the effectiveness parameter in an economic evaluation
(for a full economic evaluation, the effectiveness reviewPage 2 of 11
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inform ranges of values for the other key parameters in the
economic model).
As such, the interfaces between evidence-based economic
evaluation and Cochrane and Campbell review methods
are bilateral and multifaceted. Whilst on one hand a
Cochrane or Campbell review can provide useful and
applicable data for an evidence-based economic evalua-
tion, full economic evaluation studies and other econom-
ics studies (e.g. costing studies) can also be included in a
critical review of the extant economics literature that may
be undertaken as an integrated component of a Cochrane
(or Campbell) review. Some methodological research has
already been undertaken to examine the use of Cochrane
and other effectiveness reviews and the Cochrane Library
in evidence-based economic evaluations [6,9]. However,
patterns of use of economics methods within Cochrane
reviews remain unclear.
The Campbell & Cochrane Economics Methods Group
(CCEMG) was formally approved and registered as a
methods group for The Cochrane Collaboration in 1998,
and as a joint methods group with The Campbell Collab-
oration since 2004. CCEMG's aims and scope, reported
elsewhere, encompass development of evidence-based
economic evaluation methods and economics advice for
reviewers [10].
This paper reports a rapid review of existing Cochrane
reviews which focus on the effectiveness of health promo-
tion and public health interventions. The main aim of the
study, undertaken on behalf of CCEMG, was to examine
approaches to incorporating economics studies and data
that have been utilised in such reviews to date. A better
understanding of these issues can help to inform the
development of evidence-based guidance for reviewers on
methods for making reviews more useful to economic
decisions.
The reason for choosing to look at Cochrane reviews was
because, being a much newer collaboration, fewer Camp-
bell reviews are yet published. The topic area 'health pro-
motion and public health' was chosen because many
health promotion and public health interventions, whilst
aiming to influence health outcomes and resources, are
organised across sectors (e.g. health, education, social
care, criminal justice) and are likely to have important
impacts on outcomes and resource use beyond the health
sector, and because a key aim of the study was to pilot a
review methodology in preparation for a systematic
review of economics methods in both Cochrane Collabo-
ration and Campbell Collaboration systematic reviews,
encompassing reviews of complex and multi-sector inter-
ventions, as well as interventions in health care, health
promotion and public health, mental health, education,
criminal justice and social welfare.
Methods
The Cochrane Database of Systematic Reviews, Cochrane
Library (2005, Issue 3) was searched using a search strat-
egy for economic studies. This was adapted from an estab-
lished search strategy used by the UK Centre for Reviews
and Dissemination to identify potential economic evalu-
ations within Ovid CD-ROM versions of Current Con-
tents – Clinical Medicine, Medline and CINAHL databases
as part of the process of maintaining the NHS Economic
Evaluation Database [11], published as part of the
Cochrane Library. The strategy was used to search the title,
abstract and keyword fields within records of both com-
pleted reviews and review protocols held in the Cochrane
Database of Systematic Reviews [12]. The search was con-
ducted on 4th August 2005. The full search strategy was as
follows:
(econom*, cost*, pric*, pharmacoecon*, cost NEXT
(effectiveness, utili*, benefit, minimi*, energy, oxygen,
metabolic), (expenditure NOT energy), (value NEAR/2
money), budget*, preference, qaly, (quality NEXT
adjusted), utility, utilities, financ* NEXT (management,
support, organized))
The Cochrane Health Promotion and Public Health Field
maintains an online list of Cochrane reviews and review
protocols identified as relevant to health promotion and
public health [13]. Reviews and review protocols were
included if they appeared on both the latter list and the
list of record titles retrieved by the search. Full reports of
included reviews and review protocols were assessed to
establish details of the economics component of each
review. Data describing the economics component of
reviews were extracted, coded, tabulated, analysed quali-
tatively and summarised by one researcher, working inde-
pendently.
For those reviews which aim to incorporate economics
studies, initial focussed searches for additional, relevant
full economic evaluation studies (not included in the
review) were conducted in the NHS Economic Evaluation
Database, using search strategies that were developed by
combining search terms used in the corresponding review
with MeSH terms used to index the corresponding review.
Results
A 'Quorum Statement' flow-diagram is included as Figure
1. The initial search of the Cochrane Database of Systematic
Reviews, to identify economic references in existing
reviews and protocols, identified 483 records out of 4041
records held in the database. One record was excluded at
this stage since the corresponding review has been with-Page 3 of 11
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completed Cochrane reviews. Seventy-seven records con-
tained protocols for Cochrane reviews – reviews which are
registered but not yet completed.
Twenty-one of the 405 completed reviews retrieved by the
initial search are also listed as relevant to health promo-
tion and public health [[22-42] in Table 1]. As such,
approximately 11% of the total number of completed
reviews identified as relevant to health promotion and
public health contain economics references (21 of 186).
These 21 reviews spanned a wide range of health promo-
tion and public health topics (e.g. mental and social
health; population screening; prevention of infectious dis-
ease; prevention of injuries; sexual health; cardiovascular
health). Additionally, 7 of the 77 review protocols
retrieved by the initial search are also listed as relevant to
health promotion and public health [[43-49] in Table 1].
This represents approximately 4% of the total number of
review protocols identified as relevant to health promo-
tion and public health (7 of 162).
Approaches to incorporating economics studies or data
The principal findings from this rapid review are summa-
rised in Table 1. It is evident that none of these 21 com-
pleted reviews, or 7 review protocols, incorporates formal
economic evaluation methods (i.e. a cost-consequences,
cost-effectiveness, cost-utility, or cost benefit analysis).
That is, none of the reviews includes an aim to model the
joint distribution of incremental costs and effects result-
ing from the interventions studied, compared to relevant
alternatives, based on a synthesis of the results of studies
included in the review.
Ten of 21 completed reviews do aim explicitly to incorpo-
rate economics studies and/or data into the review (4 of 7
protocols include this explicit aim). However, none of
these ten reviews describe either a specific methodological
approach (e.g. a systematic review of economic evaluation
studies) or specific methods (e.g. search strategies, critical
appraisal, inclusion criteria, analytic methods) underpin-
ning incorporation of such studies and data.
One review protocol does include a clear description of
the specific methodological approach that will underpin
incorporation of economics studies and data. Ilic et al
include, as a secondary objective, to "conduct a systematic
review of studies regarding the economic evaluation of
screening for prostate cancer. This will aim to identify the
cost effectiveness, cost utility and cost-benefit of mass
screening for prostatic cancer" [48].
It is, however, possible to establish some details of the
approaches pursued in the ten completed reviews that
explicitly aim to incorporate economics studies and data.
Four of these ten reviews include a specific economic
question or objective to be addressed in the systematic
review (alongside the main focus on intervention effec-
tiveness) [22,23,27,42]. For example, Hey and Perrera
[23] ask, "What are the cost implications of providing
incentives and competitions for smoking cessation?",
whilst Ashworth et al [27] ask, "Which exercise pro-
grammes are the most cost-effective?" Note that the eco-
nomic question formulated by Hey and Perrera [23]
implies a concern with evidence related to the distribution
of costs associated with the interventions being studied,
whilst the question formulated by Ashworth et al [27]
implies a concern with evidence related the joint distribu-
tion of costs and effects associated with the interventions,
or cost-effectiveness (as did the objective in the Ilic et al
protocol [48]).
Seven of the ten reviews aiming to incorporate economics
studies and data [25,27,30,33,35,39,40] include one or
more economic variables – measures of cost, resource use
or service utilisation – as outcomes of interest in the
review, alongside other 'effectiveness' outcomes. For
Quorum statement flow diagramFigu e 1
Quorum statement flow diagram.
Records of reviews (& 
protocols) identified as relevant 
to health promotion and public 
health identified and screened 
for retrieval:  
n = 186 (162)
Records of reviews (& 
protocols) excluded because 
the corresponding review did 
not include economics 
references: 
n = 164 (155) 
Records of reviews (& protocols) 
excluded because the 
corresponding review has been 
withdrawn from the Cochrane 
Library: 
n = 1 (0) 
Records of reviews (& 
protocols) with usable 
information:  
n = 21 (7) 
Records of reviews (& 
protocols) retrieved for more 
detailed evaluation:  
n = 22 (7) Page 4 of 11
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Table 1: Results
No. Approach to incorporating economics studies and/or data Analysis of economics studies and/or data Other issues
Review aims 
to include 
economics 
studies
Review aims 
to incorporate 
formal 
economic 
evaluation 
methods
Review 
includes a 
specific 
economic 
question
Review 
specifies one 
or more 
economic 
variable(s) as a 
review 
outcome
Review 
identified no 
primary 
studies 
incorporating 
economic 
evaluation 
methods or 
other 
economic 
analyses
Review 
includes a 
narrative 
summary of 
economics 
data extracted 
from included 
studies
Review 
incorporates a 
quantitative 
synthesis of 
economic 
variables 
extracted 
from included 
studies
Review 
incorporates a 
search of one 
or more 
specialist 
databases of 
economics 
studies 
(e.g. NHS EED)
(Further) 
potentially relevan
economic 
evaluation studies
identified by initia
NHS EED searche
for potential 
inclusion in an 
updated review
22 • • •
23 • • • •
24 n/a
25 • • •
26 • n/a
27 • • • •
28 n/a
29 n/a
30 • • • •
31 •
32
33 • • • •
34 n/a
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35 • • • •
36 n/a
37 n/a
38 n/a
39 • • •
40 • • • Not Clear •
41
42 • • • •
Total 10 0 4 7 6 6 0 1 5
43 n/a n/a n/a n/a n/a
44 n/a n/a n/a n/a n/a
45 n/a n/a n/a n/a n/a
46 • • n/a n/a n/a n/a n/a
47 • • • n/a n/a n/a n/a n/a
48 • • • n/a n/a n/a n/a n/a
49 • • • n/a n/a n/a n/a n/a
Total 4 0 4 3 - - - - -
Table 1: Results (Continued)
BMC Medical Research Methodology 2006, 6:55 http://www.biomedcentral.com/1471-2288/6/55example, Kujan et al [39] include "costs" in a set of sec-
ondary outcomes alongside "incidence of oral cancer or
potentially premalignant oral lesions", "mortality at three
or more years" and "stage of diagnosis" ("oral cancer spe-
cific mortality" is selected as the primary outcome of inter-
est in this review). Similarly, Chilvers et al [40] include
"capital expenditure", "total cost of care per tenant or
respondent" and "total health costs per tenant or respond-
ent" in a set of secondary 'economic outcomes'. It is of
note that in this second example [40], specific compo-
nents of intervention 'costs' are clearly described, whilst in
the first [39], it is comparatively unclear which elements
of 'costs' will be considered. All economic variables speci-
fied as outcomes in these Cochrane reviews imply a con-
cern with evidence related to the distribution of costs (or
resource use) associated with the interventions being
studied, as opposed to evidence on cost-effectiveness.
None of the ten completed reviews aiming to incorporate
economics studies and data appears to include use of sup-
plementary search strategies designed specifically to cap-
ture economics studies and data other than those
conducted alongside those studies captured in searches
specified for the effectiveness review. Also, only one of
these ten reviews explicitly includes a search of one or
more specialist electronic databases of economics studies
[33] (one protocol, incorporating plans for a systematic
review of relevant economic evaluation studies, signals an
intention to include such a search [48]). The extent to
which search strategies for relevant economics studies and
data extended beyond those studies identified and
retrieved for the effectiveness review is therefore unclear.
Analysis of economics studies and data
Five of the 10 completed reviews aiming to incorporate
economics studies and data (plus one other review which
did not explicitly seek such studies or data [26]) indicate
that no such relevant studies or data are identified
[22,26,27,30,39,40]. This would clearly preclude any
form of analysis intending to utilise such studies or data.
However, some reviews – including at least one review
which sought, but did not identify any such studies or
data [30] – are likely to have missed potentially relevant
economics studies that could have been identified
through searches using the NHS Economic Evaluation
Database (NHS EED) [14] and/or other specialist elec-
tronic databases of economics studies.
For example, our own searches of NHS EED, conducted to
inform this rapid review, identified a small number of
additional potentially relevant economic evaluation stud-
ies that had not been identified in the corresponding
Cochrane review. One or more additional, potentially rel-
evant economic evaluation studies were identified for 5 of
the 10 reviews that include an aim to incorporate eco-
nomics studies and data [23,30,35,40,42] (although in
two of these five cases, a single additional economic eval-
uation has been published since the last substantive
update of the corresponding Cochrane review [23,40]).
These additional economics evaluation studies were
based either on a review and synthesis of primary studies,
or on effectiveness data from sources other than the types
of studies (primarily randomised trials) targeted for the
Cochrane effectiveness review. It is also worth highlight-
ing that a majority (although not all) relevant economic
evaluation studies which had been identified across these
21 Cochrane reviews have a corresponding full abstract
record in the NHS Economic Evaluation Database.
The other 5 completed reviews aiming to incorporate eco-
nomics studies and data (with the addition of one other
review which did not explicitly seek such studies or data
[31]) include a narrative summary of relevant findings in
economics studies identified in the review
[23,25,31,33,35,42]. For example, Forbes et al [33]
include a summary of cost data reported alongside two
included randomised controlled trials – one appears to be
a costing study which presents data on total estimated
costs of the interventions for each intervention group;
another appears to be an economic evaluation which
presents data on the estimated incremental costs of the
interventions per additional diagnostic test (cervical
smear test) performed, compared with usual care. Lees et
al [35] include a narrative summary of the general conclu-
sions of three economic evaluations of neonatal screening
programmes, whilst Gillespie et al [31] include a narrative
summary of cost-effectiveness estimates (cost per fall pre-
vented) extracted from five included randomised control-
led trials that had incorporated economic evaluations.
None of the reviews incorporating a narrative summary
which focuses on the costs of the interventions (e.g. pre-
senting data on the incremental costs of resource inputs
required for an intervention) includes adjustment of such
data for currency and inflation, and only one presents
data in such a way that would allow such adjustments to
be undertaken subsequently [31]. Also, none of these nar-
rative summaries include critical appraisal of the method-
ological quality of included economics studies, or
commentary on the economic questions, costing methods
and analytic viewpoints adopted in such studies. None of
the completed reviews incorporates a quantitative synthe-
sis of measures of cost or resource use, extracted from
included primary studies (e.g. meta-analysis).
Other issues relevant to economics methods
Three completed reviews draw attention to the point that
economic analyses of the interventions are not currently
appropriate, due to inconclusive or methodologically
weak evidence, or a lack of evidence of intervention effec-Page 7 of 11
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[23,26,40]. More generally, only 6 of the 21 Cochrane
reviews considered in this rapid review find that the inter-
vention(s) studied show evidence of 'effectiveness', or 'a
positive effect' (including those which show 'good evi-
dence', or 'strong evidence' of effectiveness) [24-
26,30,38,42]. Three of these 6 reviews aim to include eco-
nomics studies or data [25,30,42], of which one [42] has
been found to have missed a small number of potentially
relevant economic evaluation studies. The other 15
reviews either conclude that there is: no evidence
[22,29,32,35,39,40]; no clear evidence of effectiveness
[23,26,27]; weak evidence of effectiveness [37,41]; evi-
dence of mixed effectiveness (i.e. the intervention was
found to be effective in some groups but not necessarily in
others) [31,33,34]; or some evidence of ineffectiveness
[36].
Eleven of 21 completed reviews highlight a need for future
primary research incorporating economic evaluation
methods in order to establish evidence on intervention
cost-effectiveness [22,25,27,29-34,38,42]. This included
two reviews for which additional, potentially relevant eco-
nomic evaluations have been identified through initial
searches of the NHS economic evaluation database (con-
ducted to inform this rapid review) [30,42].
Finally, three other reviews amongst the 21 considered in
this rapid review were retrieved by the initial search of the
Cochrane Library because the review covers discussion of
one or more relevant economic aspects of the populations
or interventions being studied [24,28,37]. In most cases
the scope of this discussion relates to economic factors as
determinants of epidemiology, patterns of intervention
provision or uptake, or potential economic consequences
of interventions. For example, Shepherd et al highlight the
higher incidence of cervical cancer amongst women of
lower socio-economic class than amongst middle class
women in Britain [28], whilst Zoritch et al highlight that
different levels of day-care provision in part reflect cul-
tural and economic interests concerning the welfare of
children and the need to promote mothers' participation
in paid work [24].
Discussion
This rapid review has shown that relatively few Cochrane
systematic reviews relevant to health promotion and pub-
lic health incorporate an economics dimension. It is also
clear however that a sizable minority of Cochrane review-
ers are aware that their topic of review has economic
implications and wish to report this aspect. The review has
further shown that where such reviews do incorporate
economics studies and data, methodological approaches
vary considerably, and the methods used are not consist-
ently reported. The extent to which these principal find-
ings are reflected across all Cochrane reviews may usefully
be explored further.
It was not anticipated that the Cochrane reviews included
in this study would widely incorporate formal economic
evaluation methods. The Cochrane Collaboration has
always aimed to produce high quality reviews of effects of
health care interventions in order to support decisions
which also need information from other sources. How-
ever, since Cochrane reviews aim to have international
applicability, it is not currently clear how incorporation of
full economic evaluation methods could be constructively
achieved within such reviews [15]. This is because full eco-
nomic evaluation involves estimation of the joint distri-
bution of incremental costs and effects (cost-
effectiveness) accruing from an intervention, compared to
relevant alternatives, for specific populations, jurisdic-
tions, or settings. Such estimates are sensitive to variability
across settings in local prices (cost), the organisation of
care (resource use) and values attached to specific health
related outcomes (e.g. utilities) [16-18] and this may limit
the generalisability or transferability of such estimates
across settings (e.g. across different nations). Conversely,
there is a general belief that relative clinical effectiveness
(or 'relative risk reduction') is not influenced by jurisdic-
tion and setting (although absolute risk reduction is
dependent on baseline levels of risk in a given population,
which is variable across settings). Whilst this naturally
militates against the incorporation of formal economic
evaluation methods into Cochrane reviews, it does not
preclude the use of data from Cochrane reviews in paral-
lel, or subsequent jurisdiction specific economic evalua-
tion studies. It should also be noted that for the same
reasons, there are currently no agreed upon methods for
combining incremental cost-effectiveness, cost-utility or
cost-benefit ratios from multiple studies.
The results also indicate that this set of Cochrane reviews
rarely select studies on the basis that they meet criteria for
being classified as full economic evaluations, such as
those defined by Drummond et al [4,19]. Rather, studies
are selected based on inclusion criteria set for the effective-
ness review (with a focus on randomised trials). As such,
this set of Cochrane reviews considers only those econom-
ics studies conducted alongside studies eligible for inclu-
sion in the effectiveness review. This may exclude relevant
data contained in full economic evaluations based on
reviews of existing trials, those based on effectiveness data
from sources other than randomised controlled trials, and
other economics studies, or partial economic evaluations
(e.g. costing studies).
Use of searches specifically tailored to the retrieval of rel-
evant economics studies, and searches of specialist data-
bases, such as NHS EED, would help to address thisPage 8 of 11
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tion of such searches can prove fruitful. Additionally,
reviewers considering the economic perspective should
consider undertaking classification of the economics stud-
ies encountered in a review, and critical appraisal of their
methodological quality, using a purpose-specific, estab-
lished checklist prior to the final decision to include or
exclude such studies [19,20].
Although the CCEMG has existed for nearly a decade, evi-
dence-based guidance on handling economic issues in
Cochrane Reviews has not been covered specifically in the
Cochrane Reviewers' Handbook. Reviewers have had
access to workshops at annual meetings and to informal
advice from the members of the economics methods
group. Perhaps linked to this lack of agreed approach, the
methods used to derive cost and resource use, or cost-
effectiveness estimates in primary studies are not consist-
ently critiqued in this set of Cochrane reviews.
Some of the reviews report economic outcomes that were
measured within one or more trials. Economics studies
will vary in their results because the economic question
and analytic viewpoint varies between studies, and so the
variables included and the values given to them are spe-
cific to the study [15]. Formal critique of included eco-
nomics studies is required to clarify, for the users of
reviews, whether such estimates consist of comparable, or
homogeneous, cost, or resource use components.
Even where it is not appropriate to combine cost or
resource use data, cost or resource use estimates from sev-
eral primary studies can provide a range of values for cost
and resource use parameters in a sensitivity analysis that
may be conducted as part of a parallel or subsequent eco-
nomic evaluation based on the review. Allied to this, esti-
mates of monetary cost could be adjusted for currency and
inflation, in order to facilitate comparison of estimates
across several included studies.
More generally, the intended scope of overall analytic
approaches to economics studies and data is often unclear
in this set of Cochrane reviews. Although we found none
in this study, other Cochrane reviews include measures of
cost and/or resource use as review outcomes with the
intention of extracting these data from relevant economics
studies and producing pooled estimates of incremental
costs or incremental resource use using meta-analysis [e.g.
[21]], including a test for heterogeneity (this is the same
basic approach as that taken to the meta-analysis of effect-
size and adverse effects data in Cochrane and other effec-
tiveness reviews). When presented alongside the pooled
estimates of effect-size (i.e. separate estimation of the dis-
tribution of costs and the distribution of effects), these
data can provide an indication of the quadrant of the
'cost-effectiveness plane' that an intervention is likely to
fall within. This is potentially useful information that can
help determine whether further economic evaluation is
warranted.
However, it is not clear in this set of Cochrane reviews
how those including economic variables originally
intended to analyse them. It is therefore not possible to
judge whether intended aims were fulfilled with respect to
the economics components of the reviews. This situation
could be improved with more consistent reporting of
intended methods.
Finally, it could be argued that economic decisions should
only be made on the basis of strong evidence of interven-
tion effectiveness and that, by implication, Cochrane
reviews should concentrate on establishing evidence of
effectiveness before any decision to include an economics
dimension. However, at the point of planning a Cochrane
review, it is likely that economic decisions are being, or
have already been taken about the technology being stud-
ied. It therefore seems to the authors that there is likely to
be additional value to end-users in a systematic review
which refers to the existing economics evidence, whatever
the current status of the effectiveness evidence. This may
allow decision makers using the review to place the tech-
nology on the cost-effectiveness plane [7]. For example, if
a review concludes that there is evidence of no statistically
significant difference between comparator interventions
(clinical effectiveness), then critical review of existing eco-
nomics evidence can help to establish, given similar clin-
ical effectiveness, which intervention is less costly?
Conclusion
Cochrane reviews of the effects of health care interven-
tions are used in economic decisions in a wide range of
settings, and many review groups are aware of this. Within
the Cochrane Collaboration, diverse methods for address-
ing economics issues have evolved, and we are convinced,
from the results of this review, of the value of developing
guidance for reviewers wishing to incorporate economics
aspects in their review.
Evident variability across approaches to economics stud-
ies and data in Cochrane reviews, all within a single,
broad topic area, indicates a clear need for evidence-based
guidance for Cochrane reviewers on whether and how to
incorporate economics methods into the systematic
review process, at different levels. Such guidance will need
to promote a consistent approach to the reporting of the
economics components of such reviews. There is a also
need for increased dialogue between Cochrane reviewers
and economists to develop the capacity for economic
analyses alongside Cochrane reviews, for example to
decide on the need to consider economic aspects, to setPage 9 of 11
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nomic issues around a technology, and to refer to other
studies of the economics of the technology being evalu-
ated.
The current study has also indicated that Cochrane
reviews may require a specific approach to guidance on
methods, distinct from generally available advice on eco-
nomic evaluation and Health Technology Assessment,
given the aim of the Cochrane Collaboration to provide
an international source of evidence on effects of health
related interventions. However, whilst economics meth-
ods in a global context. are likely to be distinct from those
underpinning evidence-based full economic evaluations,
they nevertheless feature on the same methodological
continuum.
That is, the analytic framework provided by economic
evaluation can help Cochrane reviewers to formulate an
integrated systematic review of relevant economics stud-
ies, alongside the review of effectiveness studies, but
which need not necessarily be restricted to the economics
components of included effectiveness studies. This type of
full critical review, including coverage of all the economic
analyses of the economics of interventions, can provide
users of the review with the international context within
which economics data can be interpreted and assessed as
a preliminary to use of evidence-based economic evalua-
tion methods.
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